PUBLICATIONS

2024

Berríos KN, Barka A, Gill J, Serrano JC, Bailer PF, Parker JB, Evitt NH, Gajula KS, Shi J*, Kohli RM*. Cooperativity between Cas9 and hyperactive AID establishes broad and diversifying mutational footprints in base editors. Nucleic Acids Res. 2024 Jan.

(*co-corresponding author).

Huang P, Peslak SA, Shehu V, Keller CA, Giardine BM, Shi J, Hardison RC, Blobel GA, Khandros E. Let-7 miRNAs repress HIC2 to regulate BCL11A transcription and hemoglobin switching. Blood. 2024 Feb

2023

Sroka MW, Skopelitis D, Vermunt MW, Preall JB, El Demerdash O, de Almeida LMN, Chang K, Utama R, Gryder B, Caligiuri G, Ren D, Nalbant B, Milazzo JP, Tuveson DA, Dobin A, Hiebert SW, Stengel KR, Mantovani R, Khan J, Kohli RM, Shi J, Blobel GA, Vakoc CR. Myo-differentiation reporter screen reveals NF-Y as an activator of PAX3-FOXO1 in rhabdomyosarcoma. PNAS. 2023 Sept.

Zhou N, Choi J, Grothusen G, Kim BJ, Ren D, Cao Z, Liu Y, Li Q, Inamdar A, Beer T, Tang HY, Perkey E, Maillard I, Bonasio R, Shi J, Ruella M, Wan L, Busino L. DLBCL-associated NOTCH2 mutations escape ubiquitin-dependent degradation and promote chemoresistance. Blood. 2023 Sept.

Wu JE, Manne S, Ngiow SF, Baxter AE, Huang H, Freilich E, Clark ML, Lee JH, Chen Z, Khan O, Staupe RP, Huang YJ, Shi J, Giles JR, Wherry EJ. In vitro modeling of CD8+ T cell exhaustion enables CRISPR screening to reveal a role for BHLHE40. Sci Immunol. 2023 Aug.

Barka A, Kohli RM*, Shi J*. CRISPR tiling screen reveals cancer epigenetic 'Goldilocks' state. Trends Pharmacol Sci. 2023 Jun. (*co-corresponding author).

Baxter AE, Huang H, Giles JR, Chen Z, Wu JE, Drury S, Dalton K, Park SL, Torres L, Simone BW, Klapholz M, Ngiow SF, Freilich E, Manne S, Alcalde V, Ekshyyan V, Berger SL, Shi J*, Jordan MS*, Wherry EJ*. The SWI/SNF chromatin remodeling complexes BAF and PBAF differentially regulate epigenetic transitions in exhausted CD8+ T cells. Immunity. 2023 Jun. (*co-corresponding author).

Qin K, Lan X, Huang P, Saari MS, Khandros E, Keller CA, Giardine B, Abdulmalik O, Shi J, Hardison RC, Blobel GA. Molecular basis of polycomb group protein-mediated fetal hemoglobin repression. Blood. 2023 Jun.

Zhang Z, Baxter AE, Ren D, Qin K, Chen Z, Collins SM, Huang H, Komar CA, Bailer PF, Parker JB, Blobel GA, Kohli RM, Wherry EJ*, Berger SL*, Shi J*. Efficient engineering of human and mouse primary cells using peptide-assisted genome editing. Nat Biotechnol. 2023 Apr. (*co-corresponding author).

Gonskikh Y, Stoute J, Shen H, Budinich K, Pingul B, Schultz K, Elashal H, Marmorstein R, Shi J, Liu KF. Noncatalytic regulation of 18 S rRNA methyltransferase DIMT1 in acute myeloid leukemia. Genes Dev. 2023 Apr.

Qiu J, Xu B, Ye D, Ren D, Wang S, Benci JL, Xu Y, Ishwaran H, Beltra JC, Wherry EJ, Shi J, Minn AJ. Cancer cells resistant to immune checkpoint blockade acquire interferon-associated epigenetic memory to sustain T cell dysfunction. Nat Cancer. 2023 Jan.

Sun X, Klingbeil O, Lu B, Wu C, Ballon C, Ouyang M, Wu XS, Jin Y, Hwangbo Y, Huang YH, Somerville TDD, Chang K, Park J, Chung T, Lyons SK, Shi J, Vogel H, Schulder M, Vakoc CR, Mills AA. BRD8 maintains glioblastoma by epigenetic reprogramming of the p53 network. Nature. 2023 Jan.

2022

Pingul BY, Huang H, Chen Q, Alikarami F, Zhang Z, Qi J, Bernt KM, Berger SL, Cao Z*, Shi J*. Dissection of the MEF2D-IRF8 transcriptional circuit dependency in acute myeloid leukemia. iScience. 2022 Sep 15;25(10):105139. (*co-corresponding author)

Liu Y, Li Q, Alikarami F, Barrett DR, Mahdavi L, Li H, Tang S, Khan TA, Michino M, Hill C, Song L, Yang L, Li Y, Pokharel SP, Stamford AW, Liverton N, Renzetti LM, Taylor S, Watt GF, Ladduwahetty T, Kargman S, Meinke PT, Foley MA, Shi J, Li H, Carroll M, Chen CW, Gardini A, Maillard I, Huggins DJ, Bernt KM, Wan L. Small-molecule inhibition of the acyl-lysine reader ENL as a strategy against acute myeloid leukemia. Cancer Discov. 2022 Sep 2;CD-21-1307.

Wakabayashi A, Kihiu M, Sharma M, Thrasher AJ, Saari MS, Quesnel-Vallieres M, Abdulmalik O, Peslak SA, Khandros E, Keller CA, Giardine BM, Barash Y, Hardison RC, Shi J, Blobel GA. Identification and characterization of RBM12 as a novel regulator of fetal hemoglobin expression. Blood Advances. 2022 May 27

Qin K, Huang P, Feng R, Keller CA, Peslak SA, Khandros E, Saari MS, Lan X, Mayuranathan T, Doerfler PA, Abdulmalik O, Giardine B, Chou ST, Shi J, Hardison RC, Weiss MJ, Blobel GA. Dual function NFI factors control fetal hemoglobin silencing in adult erythroid cells. Nature Genetics. 2022 May 26.

Cucolo L, Chen Q, Qiu J, Yu Y, Klapholz M, Budinich KA, Zhang Z, Shao Y, Brodsky IE, Jordan MS, Gilliland DG, Zhang NR, Shi J, Minn AJ. The interferon-stimulated gene RIPK1 regulates cancer cell intrinsic and extrinsic resistance to immune checkpoint blockade. Immunity. 2022 Apr 12.

Giles JR, Manne S, Freilich E, Oldridge DA, Baxter AE, George S, Chen Z, Huang H, Chilukuri L, Carberry M, Giles L, Weng NP, Young RM, June CH, Schuchter LM, Amaravadi RK, Xu X, Karakousis GC, Mitchell TC, Huang AC, Shi J, Wherry EJ. Human epigenetic and transcriptional T cell differentiation atlas for identifying functional T cell-specific enhancers. Immunity. 2022 Mar.

2021

Berríos KN, Evitt NH, DeWeerd RA, Ren D, Luo M, Barka A, Wang T, Bartman CR, Lan Y, Green AM, Shi J*, Kohli RM*. Controllable genome editing with split-engineered base editors. Nature Chemical Biology, 2021 Oct (*co-corresponding author).

Cao Z, Budinich KA, Huang H, Ren D, Lu B, Zhang Z, Chen Q, Zhou Y, Huang Y-H, Alikarami F, Kingsley M, Lenard AK, Wakabayashi A, Khandros E, Bailis W, Qi J, Carroll MP, Blobel GA, Faryabi RB, Bernt KM, Berger SL, Shi J. ZMYND8-regulated IRF8 transcription axis is an acute myeloid leukemia dependency. Molecular Cell, 2021, Jul.

Chen Z, Arai E, Khan O, Zhang Z, Ngiow SF, He Y, Huang H, Manne S, Cao Z, Baxter AE, Cai Z, Freilich E, Ali MA, Giles JR, Wu JE, Greenplate AR, Hakeem MA, Chen Q, Kurachi M, Nzingha K, Ekshyyan V, Mathew D, Wen Z, Speck NA, Battle A, Berger SL, Wherry JE*, Shi J*. In vivo CD8 T cell CRISPR screening reveals control by Fli1 in infection and cancer. Cell, 2021 Mar (*co-corresponding author).

Yao C, Lou G, Sun HW, Zhu Z, Sun Y, Chen Z, Chauss D, Moseman EA, Cheng J, D'Antonio MA, Shi W, Shi J, Kometani K, Kurosaki T, Wherry EJ, Afzali B, Gattinoni L, Zhu Y, McGavern DB, O'Shea JJ, Schwartzberg PL, Wu T. BACH2 enforces the transcriptional and epigenetic programs of stem-like CD8 + T cells. Nat Immunology, 2021 Feb.

Verma P, Zhou Y, Cao Z, Deraska PV, Deb M, Arai E, Li W, Shao Y, Li Y, Puentes L, Patankar S, Mach RH, Faryabi RB, Shi J*, Greenberg RA*. ALC1 links chromatin accessibility to PARP inhibitor response in homologous recombination deficient cells. Nature Cell Biology, 2021 Jan. (*co-corresponding author)

Torre EA, Arai E, Bayatpour S, Beck LE, Emert BL, Shaffer SM, Mellis IA, Fane M, Alicea G, Budinich KA, Weeraratna A, Shi J*, Raj A*. Genetic screening for single-cell variability modulators driving therapy resistance. Nature Genetics, 2021 Jan. (*co-corresponding author)

2020

Lan X, Ren R, Feng R, Ly LC, Lan Y, Zhang Z, Aboreden N, Qin K, Horton JR, Grevet JD, Mayuranathan T, Abdulmalik O, Keller CA, Giardine B, Hardison RC, Crossley M, Weiss MJ, Cheng X, Shi J*, Blobel GA*. ZNF410 Uniquely Activates the NuRD Component CHD4 to Silence Fetal Hemoglobin Expression. Molecular Cell, 2020 Dec. (*co-corresponding author)

Peslak SA, Khandros E, Huang P, Lan X, Geronimo CL, Grevet JD, Abdulmalik O, Zhang Z, Giardine BM, Keller CA, Shi J, Hardison RC, Blobel GA. HRI depletion cooperates with pharmacologic inducers to elevate fetal hemoglobin and reduce sickle cell formation. Blood Adv, 2020 Sep.

Gier, R.A., Budinich, K.A., Evitt, N.H., Cao, Z., Freilich, E., Chen, Q., Qi, J., Lan, Y., Kohli, R., and Shi, J*. High-performance CRISPR-Cas12a genome editing for combinatorial genetic screening. Nature Communications, 2020 Jul.

Huang P, Peslak SA, Lan X, Khandros E, Yano JA, Sharma M, Keller CA, Giardine B, Qin K, Abdulmalik O, Hardison RC, Shi J*, Blobel GA*. The HRI-regulated transcription factor ATF4 activates BCL11A transcription to silence fetal hemoglobin expression. Blood, 2020 Jun. (*co-corresponding author)

Yuan S, Natesan R, Sanchez-Rivera FJ, Li J, Bhanu NV, Yamazoe T, Lin JH, Merrell AJ, Sela Y, Thomas SK, Jiang Y, Plesset JB, Miller EM, Shi J, Garcia BA, Lowe SW, Asangani IA, Stanger BZ. Global Regulation of the Histone Mark H3K36me2 Underlies Epithelial Plasticity and Metastatic Progression. Cancer Discovery, 2020 Jun.

2019

Bell, C.C., Fennell, K.A., Chan, Y.C., Rambow, F., Yeung, M.M., Vassiliadis, D., Lara, L., Yeh, P., Martelotto, L.G., Rogiers, A., Kremer, B.E., Barbash, O., Mohammad, H.P., Johanson, T.M., Burr, M.L., Dhar, A., Karpinich, N., Tian, L., Tyler, D.S., MacPherson, L., Shi, J., Pinnawala, N., Yew Fong, C., Papenfuss, A.T., Grimmond, S.M., Dawson, S.J., Allan, R.S., Kruger, R.G., Vakoc, C.R., Goode, D.L., Naik, S.H., Gilan, O., Lam, E.Y.N., Marine, J.C., Prinjha, R.K., Dawson, M.A. Targeting enhancer switching overcomes non-genetic drug resistance in acute myeloid leukaemia. Nature Communications 2019 10(1):2723.

Chan, K., Robert, F., Oertlin, C., Kapeller-Libermann, D., Avizonis, D., Gutierrez, J., Handly-Santana, A., Doubrovin, M., Park, J., Schoepfer, C., Da Silva, B., Yao, M., Gorton, F., Shi, J., Thomas, C.J., Brown, L.E., Porco, J.A. Jr, Pollack, M., Larsson, O., Pelletier, J., Chio, I.I.C. eIF4A supports an oncogenic translation program in pancreatic ductal adenocarcinoma. Nature Communications 2019 10(1):5151.

Ehrenhöfer-Wölfer, K., Puchner, T., Schwarz, C., Rippka, J., Blaha-Ostermann, S., Strobl, U., Hörmann, A., Bader, G., Kornigg, S., Zahn, S., Sommergruber, W., Schweifer, N., Zichner, T., Schlattl, A., Neumüller, R.A., Shi, J., Vakoc, C.R., Kögl, M., Petroczki, M., Kraut, N., Pearson, M.A., Wöhrle, S. SMARCA2-deficiency confers sensitivity to targeted inhibition of SMARCA4 in esophageal squamous cell carcinoma cell lines. Scientific Reports 2019 9(1):11661.

Kirberger, S.E., Ycas, P.D., Johnson, J.A., Chen, C., Ciccone, M.F., Woo, R.W.L., Urick, A.K., Zahid, H., Shi, K., Aihara, H., McAllister, S.D., Kashani-Sabet, M., Shi, J., Dickson, A., Dos Santos, C.O., Pomerantz, W.C.K. Selectivity, ligand deconstruction, and cellular activity analysis of a BPTF bromodomain inhibitor. Org Biomol Chem 2019 17(7):2020-2027.

Lan, X., Khandros, E., Huang, P., Peslack, S.A., Bhardwaj, S.K., Grevet, J.D., Abdulmalik, O., Wang, H., Keller, C.A., Giardine, B., Baeza, J., Duffner, E.R., El Demerdash, O., Wu, X.S., Vakoc, C.R., Garcia, B.A., Hardison, R.C., Shi, J., Blobel, G.A. The E3 ligase adaptor molecule SPOP regulates fetal hemoglobin levels in adult erythroid cells. Blood Adv 2019 3(10):1586-1597.

Petrovic J., Zhou, Y., Fasolino, M., Goldman, N., Schwartz, G.W., Mumbach, M.R.m Nguyen, S.C., Rome, K.S., Sela, Y., Zapataro, Z., Blacklow, S.C., Kruhlak, M.J., Shi, J., Aster, J.C., Joyce, E.F., Little, S.C., Vahedi, G., Pear, W.S., and Faryabi, R.B. Oncogenic Notch promotes long-range regulatory interactions within hyperconnected 3D cliques. Molecular Cell 2019 73, 1174–1190.

2018

Bin Lu, Olaf Klingbeil, Yusuke Tarumoto, Tim D. D. Somerville, Yu-Han Huang, Yiliang Wei, Dorothy C. Wai, Jason K.K. Low, Joseph P. Milazzo, Xiaoli S. Wu, Zhendong Cao, Xiaomei Yan, Osama E. Demerdash, Gang Huang, Joel P. Mackay, Justin B. Kinney, Junwei Shi*, and Christopher R. Vakoc*. A transcription factor addiction in leukemia imposed by the MLL promoter sequence. Cancer Cell. 2018 Dec 10;34(6):970-981. (* co-corresponding author)

Gerard L. Brien, David Remillard, Junwei Shi, Matthew L. Hemming, Jonathon Chabon, Kieran Wynne, Eugène T. Dillon, Gerard Cagney, Guido Van Mierlo, Marijke P Baltissen, Michiel Vermeulen, Jun Qi, Stefan Fröhling, Nathanael S. Gray, James E. Bradner, Christopher R. Vakoc and Scott A. Armstrong. Targeted degradation of BRD9 reverses oncogenic gene expression in synovial sarcoma. eLife 2018 7, e41305.

Behera V, Evans P, Face CJ, Hamagami N, Sankaranarayanan L, Keller CA, Giardine B, Tan K, Hardison RC, Shi J, Blobel GA. Exploiting genetic variation to uncover rules of transcription factor binding and chromatin accessibility. Nature Communications. 2018 Feb 22;9(1):782.

Yusuke Tarumoto, Bin Lu, Tim D. D. Somerville, Yu-Han Huang, Joseph P. Milazzo, Xiaoli S. Wu, Olaf Klingbeil, Osama E. Demerdash, Junwei Shi*, and Christopher R. Vakoc* LKB1, Salt-Inducible Kinases, and MEF2C are linked dependencies in acute myeloid leukemia. Molecular Cell. 2018 Mar 15;69(6):1017-1027. (* co-corresponding author)

Alexandra Hörmann, Barbara Hopfgartner, Thomas Köcher, Maja Corcokovic, Teresa Krammer, Christoph Reiser, Gerd Bader, Junwei Shi, Katharina Ehrenhöfer, Simon Wöhrle, Norbert Schweifer, Christopher R Vakoc, Norbert Kraut, Mark Pearson, Mark Petronczki, and Ralph A Neumüller. RIOK1 kinase activity is required for cell survival irrespective of MTAP status. Oncotarget. 2018 Jun 19;9(47):28625-28637

Yu-Han Huang, Xiaoli Wu, Olaf Klingbeil, Xue-Yan He, Gayatri Arun, Bin Lu, Tim D. D. Somerville, Joseph P. Milazzo, John E. Wilkinson, Osama E. Demerdash, David L. Spector, Mikala Egeblad, Junwei Shi, and Christopher R. Vakoc. POU2F3 is a master regulator of a tuft cell-like variant of small cell lung cancer. Genes and Development. 2018 Jul 1;32(13-14):915-928

Maria Paz Zafra, Emma M Schatoff, Alyna Katti, Miguel Foronda, Marco Breinig, Anabel Y Schweitzer, Amber Simon, Teng Han, Sukanya Goswami, Emma Montgomery, Jordana Thibado, Edward R Kastenhuber, Francisco J Sánchez-Rivera, Junwei Shi, Christopher R Vakoc, Scott W Lowe, Darjus F Tschaharganeh, and Lukas E Dow. Optimized base editors enable efficient editing in cells, organoids and mice. Nature Biotechnology. 2018 Jul 3.

Jeremy D Grevet, Xianjiang Lan, Nicole Hamagami, Christopher R Edwards, Laavanya Sankaranarayanan, Xinjun Ji, Saurabh K Bhardwaj, Carolyne J Face, David F Posocco, Osheiza Abdulmalik, Cheryl A Keller, Belinda Giardine, Simone Sidoli, Ben A Garcia, Stella T Chou, Stephen A Liebhaber, Ross C Hardison, Junwei Shi*, and Gerd A Blobel*. Domain-focused CRISPR screen identifies HRI as a fetal hemoglobin regulator in human erythroid cells. Science. 2018 Jul 20;361(6399):285-290. (* co-corresponding author)

2017

Jonathan J. Ipsaro, Chen Shen, Eri Arai, Yali Xu, Justin B. Kinney, Leemor Joshua-Tor, Christopher R. Vakoc*, and Junwei Shi*: Rapid generation of drug-resistance alleles at endogenous loci using CRISPR-Cas9 indel mutagenesis. PLoS One (2), e0172177, Feb 2017.

Singh N, Shi J, June CH, Ruella M. Genome-Editing Technologies in Adoptive T Cell Immunotherapy for Cancer. Curr Hematol Malig Rep. 2017 Dec;12(6):522-529.

Barbieri I, Tzelepis K, Pandolfini L, Shi J, Millán-Zambrano G, Robson SC, Aspris D, Migliori V, Bannister AJ, Han N, De Braekeleer E, Ponstingl H, Hendrick A, Vakoc CR, Vassiliou GS, Kouzarides T. Promoter-bound METTL3 maintains myeloid leukaemia by m6A-dependent translation control. Nature. 2017 Dec 7;552(7683):126-131.

2016

Anand S. Bhagwat, Jae-Seok Roe, Beverly Y.L. Mok, Anja F. Hohmann, Junwei Shi, Christopher R. Vakoc: BET Bromodomain Inhibition Releases the Mediator Complex from Select cis-Regulatory Elements. Cell Reports 15(3): 1-12, April 2016.

Anja F. Hohmann, Laetitia J. Martin, Jessica Minder, Jae-Seok Roe, Junwei Shi, Steffen Steurer, Gerd Bader, Darryl McConnel, Mark Pearson, Thomas Gerstberger, Teresa Gottschamel, Diane Thompson, Yutaka Suzuki, Manfred Koegl, and Christopher R. Vakoc: Sensitivity and engineered resistance of myeloid leukemia cells to BRD9 inhibition. Nature Chemical Biology 2016.

2015

Eric Wang, Shinpei Kawaoka, Jae-Seok Roe, Junwei Shi, Anja F. Hohmann, Yali Xu, Anand S. Bhagwat, Yutaka Suzuki, Justin B. Kinney and Christopher R. Vakoc: The transcriptional cofactor TRIM33 prevents apoptosis in B lymphoblastic leukemia by deactivating a single enhancer. eLife 4: e06377, 2015.

Chen Shen, Jonathan J. Ipsaro, Junwei Shi, Joseph A. Milazzo, Eric Wang, Jae-Seok Roe, Yutaka Suzuki, Darryl J. Pappin, Leemor Joshua-Tor, and Christopher R. Vakoc: NSD3-short is an adaptor protein that couples BRD4 to the CHD8 chromatin remodeler. Molecular Cell 60(6): 1-13, 2015.

Junwei Shi, Eric Wang, Joseph P. Milazzo, Zhihua Wang, Justin B Kinney, Christopher R. Vakoc. Discovery of cancer drug targets by CRISPR-Cas9 screening of protein domains. Nature Biotechnology. (2015) May 33:661-7.

2014

Junwei Shi and Christopher R. Vakoc: The mechanisms behind the therapeutic activity of BET bromodomain inhibition. Molecular Cell 54(5): 728-736, 2014.

2013

Junwei Shi*, Eric Wang*, Johannes Zuber, Amy Rappaport, Meredith Taylor, Christopher Johns, Scott W. Lowe, and Christopher R. Vakoc: The Polycomb complex PRC2 supports aberrant self-renewal in a mouse model of MLL-AF9;Nras(G12D) acute myeloid leukemia. Oncogene 32(7): 930-938, 2013. Notes: (* These authors contributed equally to this work.)

Eric Wang, Shinpei Kawaoka, Ming Yu, Junwei Shi, Ting Ni, Wenjing Yang, Jun Zhu, Robert G. Roeder and Christopher R. Vakoc. Histone H2B ubiquitin ligase RNF20 is required for MLL-rearranged leukemia. Proceedings of the National Academy of Sciences. (2013) 110: 3901-6

Bryan King, Thomas Trimarchi, Linsey Reavie, Luyao Xu, Jasper Mullenders, Panagiotis Ntziachristos, Beatriz Aranda-Orgilles, Arianne Perez-Garcia, Junwei Shi, Christopher Vakoc, Peter Sandy, Steven S. Shen, Adolfo Ferrando and Iannis Aifantis: The Ubiquitin Ligase FBXW7 Modulates Leukemia-Initiating Cell Activity by Regulating MYC Stability. Cell 153(7): 1552-1566, 2013. Notes: Comment in: Therapeutics: Embracing instability. [Nat Rev Cancer. 2013] Notching up MYC gives a LIC. [Cell Stem Cell. 2013]

Junwei Shi, Warren A. Whyte, Cinthya Zepeda-Mendoza, Joseph Milazzo, Chen Shen, Jae S. Roe, Jessica Minder, Fatih Mercan, Eric Wang, Melanie A. Eckersley-Maslin, Amy E. Campbell, Shinpei Kawaoka, Sarah Shareef, Zhu Zhu, Jude Kendall, Matthias Muhar, Christian Haslinger, Ming Yu, Robert G. Roeder, Michael A. Wigler, Gerd A. Blobel, Johannes Zuber, David L. Spector, Richard A. Young, and Christopher R. Vakoc: Role of SWI/SNF in acute leukemia maintenance and enhancer-mediated Myc regulation. Genes and Development 27(24): 2648-2662, 2013.

2012

Harald Herrmann, Katharina Blatt, Junwei Shi, Karoline V. Gleixner, Sabine Cerny-Reiterer, Leonhard Müllauer, Christopher R. Vakoc, Wolfgang R. Sperr, Hans-Peter Horny, James E. Bradner, Johannes Zuber and Peter Valent. Small-molecule inhibition of BRD4 as a new potent approach to eliminate leukemic stem- and progenitor cells in acute myeloid leukemia (AML). Oncotarget. (2012) 12:1588-99

2011

Johannes Zuber*, Junwei Shi*, Eric Wang, Amy R. Rappaport, Harald Herrmann, Edward A. Sison, Daniel Magoon, Jun Qi, Katharina Blatt, Mark Wunderlich, Meredith J. Taylor, Christopher Johns, Agustin Chicas, James C. Mulloy, Scott C. Kogan, Patrick Brown, Peter Valent, James E. Bradner, Scott W. Lowe and Christopher R. Vakoc. RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia. Nature. (2011) 478: 524-8. (* These authors contributed equally to this work.)

Johannes Zuber, Amy R. Rappaport, Weijun Luo, Eric Wang, Chong Chen, Angelina V. Vaseva, Junwei Shi, Susann Weissmueller, Christof Fellman, Meredith J. Taylor, Martina Weissenboeck, Thomas G. Graeber, Scott C. Kogan, Christopher R. Vakoc and Scott W. Lowe. An integrated approach to dissecting oncogene addiction implicates a Myb-coordinated self-renewal program as essential for leukemia maintenance. Genes and Development. (2011) 25:1628-40.

Jake E. Delmore, Ghayas C. Issa, Madeleine E. Lemieux, Peter B. Rahl, Junwei Shi, Hannah M. Jacobs, Efstathios Kastritis, Timothy Gilpatrick, Ronald M. Paranal, Jun Qi, Marta Chesi, Anna C. Schinzel, Michael R. McKeown, Timothy P. Heffernan, Christopher R. Vakoc, P. Leif Bergsagel, Irene M. Ghobrial, Paul G. Richardson, Richard A. Young, William C. Hahn, Kenneth C. Anderson, Andrew L. Kung, James E. Bradner and Constantine S. Mitsiades. BET Bromodomain Inhibition as a Therapeutic Strategy to Target c-Myc. Cell. (2011) 146: 904-17.